A part of MilliporeSigma

203811 | Bryostatin 1 - CAS 83314-01-6 - Calbiochem

203811
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Key Specifications Table

      Empirical FormulaCAS #
      C₄₇H₆₈O₁₇ 83314-01-6

      Pricing & Availability

      Catalog NumberAvailability Packaging Qty/Pack Price Quantity
      203811-10UG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service

          Glass bottle 10 μg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewA macrocyclic lactone with antitumor properties. Potently activates protein kinase C and exhibits a high binding affinity (Ki = 1.35 nM). Effectively translocates and down-regulates PKC isozymes α, δ, and ε. Induces a biphasic activation of PKD through a PKC-dependent pathway in intact cells. Also shown to activate Ras in Jurkat T cells and in rat2 cells.
          Catalogue Number203811
          Brand Family Calbiochem®
          SynonymsBryo 1, PKC Activator VII, PKC Activator VI
          References
          ReferencesClamp, A., and Jayson, G. 2002. Anticancer Drugs 13, 673.
          Lorenzo, P.S., et al. 1999. Cancer Res. 59, 6137.
          Wang, Q.J., et al. 1999. J. Biol. Chem. 274, 37233.
          Wender, P.A., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 6624.
          Matthews, S.A., et al. 1997. J. Biol. Chem. 272, 20245.
          Szallasi, Z., et al. 1994. Mol. Pharmacol. 46, 840.
          Berkow, R.L., and Kratt, A.S. 1985. Biochem. Biophys. Res. Commun. 3, 1109.
          Product Information
          CAS number83314-01-6
          ATP CompetitiveN
          FormColorless solid or film
          Hill FormulaC₄₇H₆₈O₁₇
          Chemical formulaC₄₇H₆₈O₁₇
          ReversibleN
          Structure formula Image
          Applications
          Biological Information
          Primary TargetProtein kinase C
          Primary Target K<sub>i</sub>1.35 nM for protein kinase C
          Purity≥98% by TLC
          Physicochemical Information
          Cell permeableN
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          RTECSEH9455000
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Ambient Temperature Only
          Toxicity Standard Handling
          Storage -20°C
          Protect from Light Protect from light
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          Certificates of Analysis

          TitleLot Number
          203811

          References

          Reference overview
          Clamp, A., and Jayson, G. 2002. Anticancer Drugs 13, 673.
          Lorenzo, P.S., et al. 1999. Cancer Res. 59, 6137.
          Wang, Q.J., et al. 1999. J. Biol. Chem. 274, 37233.
          Wender, P.A., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 6624.
          Matthews, S.A., et al. 1997. J. Biol. Chem. 272, 20245.
          Szallasi, Z., et al. 1994. Mol. Pharmacol. 46, 840.
          Berkow, R.L., and Kratt, A.S. 1985. Biochem. Biophys. Res. Commun. 3, 1109.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision15-May-2014 JSW
          SynonymsBryo 1, PKC Activator VII, PKC Activator VI
          DescriptionA macrocyclic lactone that exhibits anti-tumor properties. Potently activates protein kinase C and exhibits high binding affinity (Ki = 1.35 nM). Effectively translocates protein kinase C (PKC) isozymes α, β, and ε and induces a biphasic, concentration-dependent, down-regulation of PKC δ. Reported to compete with phorbol esters in binding to PKC. Stimulates protein kinase D (PKD) activity in a biphasic, PKC-dependent manner in intact cells. Also activates Ras in Jurkat T cells and in rat2 cells.
          FormColorless solid or film
          Intert gas (Yes/No) Packaged under inert gas
          CAS number83314-01-6
          RTECSEH9455000
          Chemical formulaC₄₇H₆₈O₁₇
          Structure formula
          Purity≥98% by TLC
          SolubilityDMSO (25 mg/ml) or Ethanol (25 mg/ml)
          Storage -20°C
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Toxicity Standard Handling
          Merck USA index14, 1457
          ReferencesClamp, A., and Jayson, G. 2002. Anticancer Drugs 13, 673.
          Lorenzo, P.S., et al. 1999. Cancer Res. 59, 6137.
          Wang, Q.J., et al. 1999. J. Biol. Chem. 274, 37233.
          Wender, P.A., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 6624.
          Matthews, S.A., et al. 1997. J. Biol. Chem. 272, 20245.
          Szallasi, Z., et al. 1994. Mol. Pharmacol. 46, 840.
          Berkow, R.L., and Kratt, A.S. 1985. Biochem. Biophys. Res. Commun. 3, 1109.